Study of CS-3150 in Patients With Severe Hypertension
Primary Purpose
Severe Hypertension
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
CS-3150
Sponsored by

About this trial
This is an interventional treatment trial for Severe Hypertension focused on measuring severe hypertension, grade III hypertension, mineralocorticoid receptor antagonist
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects aged 20 to 80 years at informed consent
- Subjects with severe hypertension, who do not receive any antihypertensive drugs or receive antihypertensive drug (except for potassium-sparing diuretics) during run-in period (Sitting SBP ≥ 180 mmHg or Sitting DBP ≥ 110 mmHg)
Exclusion Criteria:
- Patients who are suspected hypertensive emergency
- Secondary hypertension or malignant hypertension
- Diabetes mellitus with albuminuria
- Serum potassium level < 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive RA inhibitor)
- eGFR < 60 mL/min/1.73 m^2.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CS-3150
Arm Description
CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
Outcomes
Primary Outcome Measures
Change from baseline in sitting systolic and diastolic blood pressure
Secondary Outcome Measures
Time course of systolic and diastolic blood pressure
Proportion of patients achieving blood pressure control
Full Information
NCT ID
NCT02808026
First Posted
June 17, 2016
Last Updated
December 19, 2018
Sponsor
Daiichi Sankyo Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT02808026
Brief Title
Study of CS-3150 in Patients With Severe Hypertension
Official Title
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Patients With Severe Hypertension (Grade III)
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
June 2016 (Actual)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
February 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daiichi Sankyo Co., Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Hypertension
Keywords
severe hypertension, grade III hypertension, mineralocorticoid receptor antagonist
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CS-3150
Arm Type
Experimental
Arm Description
CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
Intervention Type
Drug
Intervention Name(s)
CS-3150
Intervention Description
CS-3150 2.5 to 5mg, orally, once daily after breakfast
Primary Outcome Measure Information:
Title
Change from baseline in sitting systolic and diastolic blood pressure
Time Frame
Baseline to end of Week 8
Secondary Outcome Measure Information:
Title
Time course of systolic and diastolic blood pressure
Time Frame
Baseline to end of Week 8
Title
Proportion of patients achieving blood pressure control
Time Frame
Baseline to end of Week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female subjects aged 20 to 80 years at informed consent
Subjects with severe hypertension, who do not receive any antihypertensive drugs or receive antihypertensive drug (except for potassium-sparing diuretics) during run-in period (Sitting SBP ≥ 180 mmHg or Sitting DBP ≥ 110 mmHg)
Exclusion Criteria:
Patients who are suspected hypertensive emergency
Secondary hypertension or malignant hypertension
Diabetes mellitus with albuminuria
Serum potassium level < 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive RA inhibitor)
eGFR < 60 mL/min/1.73 m^2.
Facility Information:
City
Sapporo
Country
Japan
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing URL
https://vivli.org/ourmember/daiichi-sankyo/
Learn more about this trial
Study of CS-3150 in Patients With Severe Hypertension
We'll reach out to this number within 24 hrs